GM1 ganglioside in Parkinson\u27s disease: Pilot study of effects on dopamine transporter binding. by Schneider, Jay S. et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Pharmacology and Experimental
Therapeutics Faculty Papers
Department of Pharmacology and Experimental
Therapeutics
9-15-2015
GM1 ganglioside in Parkinson's disease: Pilot study
of effects on dopamine transporter binding.
Jay S. Schneider








Johns Hopkins School of Medicine
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/petfp
Part of the Neurology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Pharmacology and Experimental Therapeutics Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For
more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Schneider, Jay S.; Cambi, Franca; Gollomp, Stephen M.; Kuwabara, Hiroto; Brašić, James R.; Leiby,
Benjamin E.; Sendek, Stephanie; and Wong, Dean F., "GM1 ganglioside in Parkinson's disease: Pilot
study of effects on dopamine transporter binding." (2015). Department of Pharmacology and
Experimental Therapeutics Faculty Papers. Paper 74.
http://jdc.jefferson.edu/petfp/74
Authors
Jay S. Schneider, Franca Cambi, Stephen M. Gollomp, Hiroto Kuwabara, James R. Brašić, Benjamin E. Leiby,
Stephanie Sendek, and Dean F. Wong
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/petfp/74
GM1 Ganglioside in Parkinson’s Disease: Pilot Study of Effects 
on Dopamine Transporter Binding
Jay S. Schneider, Ph.D.1, Franca Cambi, M.D., Ph.D.4, Stephen M. Gollomp, M.D.3, Hiroto 
Kuwabara, M.D., Ph.D.5, James R. Brašić, M.D., M.P.H.5, Benjamin Leiby, Ph.D.2, Stephanie 
Sendek, B.A.1, and Dean F. Wong, M.D., Ph.D.6
1Department of Pathology, Anatomy and Cell Biology and Parkinson’s Disease Research Unit, 
Thomas Jefferson University, Philadelphia, PA 19107
2Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 
Philadelphia, PA 19107
3Division of Neurology, Lankenau Medical Center, Wynnewood, PA 19096
4Dept. of Neurology, University of Pittsburgh School of Medicine and Pittsburgh VAMC, 
Pittsburgh, PA 15213
5Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological 
Science, Johns Hopkins School of Medicine, Baltimore MD 21287
6Russell H. Morgan Department of Radiology and Radiological Science, Departments of 
Psychiatry and Behavior Sciences and Solomon Snyder Department of Neuroscience, Johns 
Hopkins University School of Medicine, Baltimore MD 21287
Abstract
Objective—GM1 ganglioside has been suggested as a treatment for Parkinson’s disease (PD), 
potentially having symptomatic and disease modifying effects. The current pilot imaging study 
was performed to examine effects of GM1 on dopamine transporter binding, as a surrogate 
measure of disease progression, studied longitudinally.
Methods—Positron emission tomography (PET) imaging data were obtained from a subset of 
subjects enrolled in a delayed start clinical trial of GM1 in PD1: 15 Early-start (ES) subjects, 14 
Delayed-start (DS) subjects, and 11 Comparison (standard-of-care) subjects. Treatment subjects 
were studied over a 2.5 year period while Comparison subjects were studied over 2 years. 
Dynamic PET scans were performed over 90 minutes following injection of 
[11C]methylphenidate. Regional values of binding potential (BPND) were analyzed for several 
striatal volumes of interest.
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Results—Clinical results for this subset of subjects were similar to those previously reported for 
the larger study group. ES subjects showed early symptomatic improvement and slow symptom 
progression over the study period. DS and Comparison subjects were initially on the same 
symptom progression trajectory but diverged once DS subjects received GM1 treatment. Imaging 
results showed significant slowing of BPND loss in several striatal regions in GM1-treated subjects 
and in some cases, an increased BPND in some striatal regions was detected after GM1 use.
Interpretation—Results of this pilot imaging study provide additional data to suggest a potential 
disease modifying effect of GM1 on PD. These results need to be confirmed in a larger number of 
subjects.
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Parkinson’s disease; GM1 ganglioside; PET; dopamine transporter; caudate; putamen
1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by loss 
of dopamine-producing neurons in the substantia nigra pars compacta, loss of forebrain 
dopamine (primarily in the caudate nucleus and putamen), and a progressive worsening of 
clinical symptoms. Although improvement for many of the motor symptoms of the disease 
can be obtained with available pharmacotherapies, functional ability continues to deteriorate 
over time. Therefore, the development of disease modifying therapies is an area of intense 
interest.
GM1 ganglioside, a major constituent of neuronal plasma membranes, is associated with 
specialized signaling domains called lipid rafts 23. GM1 modulates various cell activities 
during development and plays important roles during adulthood in supporting neuronal 
function and survival 4. GM1 is highly expressed in the adult brain 4 where it modulates 
Ca2+ homeostasis5 and signal transduction, may promote lysosomal integrity6 and influence 
mitochondrial function 7, 8. In a variety of preclinical studies, administration of GM1 
following different types of lesions resulted in significant biochemical and behavioral 
recovery 9-15, with results particularly impressive in animal models of PD 1614171819202122.
Promising preclinical findings in animal models of PD have recently been translated to the 
clinic. Since previous work suggested that GM1 might have both symptomatic and disease 
modifying effects on PD 23, 24, a randomized, controlled, delayed start trial of GM1 in PD 
patients was conducted 1. Subjects with mild/moderate PD were randomly assigned to 
receive GM1 for 120 weeks (early-start (ES) group) or placebo for 24 wks. followed by 
GM1 for 96 wks. (delayed-start (DS) group). Additional subjects who received standard-of-
care (Comparison group) were followed for 96 wks. to obtain information about disease 
progression. At wk. 24, the ES group had significant improvement in the primary outcome 
measure (i.e., change in Unified Parkinson’s Disease Rating Scale (UPDRS) motor score). 
The DS group (as well as the standard-of-care Comparison group) showed a worsening of 
scores during the same period. The ES group also showed a sustained benefit out to wk. 120 
and their UPDRS scores remained below those recorded at study baseline 1. Subjects in both 
treatment groups fared better than the Comparison group subjects. As part of this study, a 
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subset of subjects who consented to undertake imaging studies were examined 
longitudinally with positron emission tomography (PET) after the intravenous (IV) bolus 
injection of [11C]methylphenidate ([11C]MP), which binds to and is used as a measure for 
the concentration of the dopamine transporter (DAT). The decline of the binding potential 
(BPND) of [11C]MP in the striatum of PD patients has been shown to be inversely correlated 
with UPDRS scores and severity of motor disability 25 and has been suggested as a marker 
of disease progression 25. The purpose of this imaging study was to evaluate potential 
effects of GM1 treatment on the integrity of striatal dopamine terminals.
2. Subjects and Methods
This study (ClinicalTrials.gov NCT00037830) was approved by the Division of Human 
Subjects Protection at Thomas Jefferson University and by the Western IRB (Johns Hopkins 
University). Written informed consent was obtained from all subjects prior to study. 
Subjects enrolled in the main delayed start clinical trial (results reported previously 1) were 
men or women between 39 and 85 years of age with a diagnosis of idiopathic PD consistent 
with the UK PD Society brain bank PD diagnostic criteria. Details of inclusion/exclusion 
criteria were discussed previously 1 and Comparison group subjects were recruited 
according to the same criteria.
PET imaging data were obtained from a subset of subjects enrolled in the main delayed start 
clinical trial 1: 15 subjects from the ES group, 14 subjects from the DS group, and 11 
subjects from the Comparison group. Treatment groups were scanned at baseline, at study 
week 24 and at approximately one and two years after that. The Comparison group was 
scanned at baseline and approximately one and two years later. Thermoplastic face masks 
were constructed and individually fitted to each subject’s face for immobilization and 
positioning for each MRI and PET scan as described by us previously 26. A transmission 
scan of 10 minutes duration was obtained using rotating germanium-68 rods before injection 
of the radiotracer. Subjects were scanned while in a practically defined “off” period as 
described previously 1. Dynamic PET scans were performed over 90 minutes in a 3D mode 
with a GE Advance PET scanner following an IV bolus injection of 740 megabecquerels 
(MBq) [20 millicuries (20 mCi)] [11C]MP. Three series of structural MRIs of the brain 
without contrast were performed 27 on a GE 1.5 T Signa MRI scanner. PET images were 
reconstructed using the back projection algorithm with a ramp filter using the software 
provided by the manufacturer correcting for attenuation, scatter, and dead-time. The 
radioactivity was corrected for physical decay to the injection time. The final spatial 
resolution of the PET images was estimated to be 5.5 and 6.1 mm full width at half 
maximum (FWHM) in the radial and tangential directions, respectively, at 10 cm radius 
from the center of the field-of-view 28. Volumes of interest (VOIs) were defined on 
structural MRIs for the caudate nucleus (CN), putamen (PU), and cerebellum (Cb; both 
hemispheres excluding white matter and the vermis) by an experienced, blinded rater (HK) 
according to methods previously reported 29. VOIs were divided into associative striatum 
(anterior putamen, aPu, and anterior and posterior caudate nucleus, aCN and pCN), motor 
striatum (posterior putamen, pPu), and limbic or ventral striatum (vS) on left and right side 
(a total of 10 VOIs) 30. VOIs were transferred from MRI to PET space according to MRI-to-
PET co-registration parameters (the co-registration module of the statistical parametric 
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mapping (SPM) software; 31, available at http://www.fil.ion.ucl.ac.uk/spm/’) to obtain time-
activity curves (TACs). Regional values of BPNDs 32 were obtained by the multilinear 
reference tissue method with 2 parameters (MRTM2) using the cerebellum as the reference 
region 33 without applying any manipulations to TACs.
Mixed effects linear regression (SAS v9.4, SAS Institute, Cary, NC) was used to 
simultaneously model BPNDs for all 10 VOIs. Fixed effects were included for Group (ES, 
DS, Comparison group), Time (0, 6, 12, 18, 24, and 30 months), and Region and all possible 
interactions. An unstructured direct product covariance structure was assumed to model 
correlation among the 10 VOIs measured at the same time and among the repeated 
measurements across time. Within the mixed effects model, changes in BPNDs were 
estimated and groups were compared with respect to change in BPNDs using appropriate 
linear contrasts. Estimated mean BPND loss over time was calculated along with 95% 
confidence limits. The analysis was intended to be exploratory and descriptive considering 
the small number of subjects studied and P-values are provided for group comparisons 
without adjustments for multiple comparisons.
3. Results
3.1 Subject Characteristics
The baseline characteristics of the imaging sub-study subjects are shown in Table 1. There 
were no significant group differences in most variables with the exception of time since 
diagnosis, in which ES and DS subjects differed from the Comparison subjects (Table 1). 
The baseline characteristics of the subjects participating in this imaging sub-study were 
comparable to the entire group of subjects who participated in the main randomized delayed 
start trial 1.
The treatment effects in the subjects participating in the imaging sub-study were similar to 
those described for the entire group of subjects who participated in the main randomized 
delayed start trial 1. In the initial 24 wks. of the study (Phase I), subjects who received GM1 
(ES subjects) showed improvement in UPDRS motor scores compared to subjects who 
received placebo (DS subjects) and Comparison group subjects, whose UPDRS motor 
scores worsened over the same time period (Figure 1). During the next phase of the study in 
which all treatment subjects received GM1 (Phase II), ES subjects showed a slow 
progression of symptoms, and by the end of the study, “off” period UPDRS motor scores 
were approximately back to the level observed at study baseline (Figure 1). During this 
second phase of the study, DS subjects showed an initial symptomatic benefit after 
switching to GM1 and by the end of the study, their UPDRS motor scores were only slightly 
higher than those observed at the end of the placebo period. The symptom progression 
trajectory for the ES and DS groups was divergent at the end of the study, as in the larger 
study group 1, suggestive of a possible disease-modifying effect of GM1.
3.2 [11C]methylphenidate ([11C]MP) Binding
The estimated mean fall in BPND from baseline was calculated for each VOI for each study 
group. In these analyses, a negative number indicates a gain in BPND and a positive number 
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indicates a loss of BPND. During the first 6 months of the study, there was less loss of BPND 
in almost all regions (except the ventral striatum) in the ES group compared to the DS group 
however this difference was statistically significant only in one region, the right posterior 
putamen (Table 2). Six months may be too short a time interval in which to observe reliable 
changes in the PET BPND or to observe potential disease modifying effects of GM1 therapy. 
However, there was either no change or a gain of BPND in 7 of the 10 VOIs analyzed in the 
ES group at 6 months vs. baseline while loss of BPND was measured in all VOIs in the DS 
group (Table 2).
The mean BPND loss from baseline to the next imaging study performed at 1 year into the 
second phase of the study was also analyzed. At this point, the ES subjects had been on 
GM1 for 18 months and the DS subjects had been on GM1 for 12 months. The Comparison 
subjects were also scanned at 12 months following their baseline scans. Overall, the ES 
subjects showed little loss of BPND after 18 months of GM1 use, compared to baseline and 
for each region analyzed, and showed less loss of BPND compared to the DS subjects and 
the Comparison group subjects (Table 3). There was less BPND loss in several striatal 
regions in the ES group 18 months after baseline (and after 18 months of GM1 use) than in 
the Comparison group over only a 12 month period (Table 3) and an apparent gain of BPND 
was still detected in some regions in the ES subjects. Even though the DS group generally 
showed less BPND loss in most striatal regions over a 12 month period of GM1 use 
compared to the BPND loss in the Comparison group over 12 months, these differences were 
not statistically significant (Table 3).
The next data analyzed were the mean BPND loss from baseline to the end of year 2 of the 
second phase of the study. At this point, the ES subjects had been on GM1 for 30 months 
and the DS subjects had been on GM1 for 24 months. The Comparison subjects were also 
scanned at 24 months following their baseline scans. In each region analyzed, there was less 
BPND loss detected in the ES subjects at this time period compared to the DS subjects and 
the Comparison group subjects. There was significantly less BPND loss in several striatal 
regions in the ES group 30 months after baseline (and after 30 months of GM1 use) than in 
the Comparison group over only a 24 month period (Table 4; Figure 2). In most regions, the 
BPND loss in the DS subjects after 24 months of GM1 use was also less than that detected in 
the Comparison group (Figure 2), although the difference was statistically significant only 
for 1 region, the right posterior caudate nucleus (Table 4).
Taking the data collected at the 6 month point of the study as a new baseline for the DS 
subjects (as they had been on placebo for the first 6 months of the study) we examined the 
BPND loss between the 6 month time point and the end of the 2 year second phase of the 
study. During this period, the DS subjects had used GM1 for 2 years. When analyzed this 
way, the DS subjects showed less loss of BPND in all regions than did the Comparison 
subjects over this 2 year period and the differences were statistically significant for 6 of the 
10 regions analyzed (Table 5).
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The results of this pilot study suggest the possibility of a slowing of BPND loss in several 
striatal regions in GM1-treated subjects and in some cases, the data suggest an increased 
BPND in some striatal regions, compared to baseline. There was less loss of BPND in ES 
subjects versus the Comparison group, measured after 18 and 30 months of GM1 use. It is 
possible that these results could have been affected by subjects in the Comparison group 
having a slightly longer time since diagnosis compared to subjects in the ES and DS groups. 
However, the decline in striatal dopamine transporter binding in early-stage PD patients 
suggest no substantial differences in the rate of annual BP decline over the first 5 to 7 years 
after symptom onset 34 ND. Also, once they switched to using GM1, the DS subjects also 
showed less BPND loss over time than did Comparison group subjects, however, consistent 
with the results of larger clinical study 1, there was an advantage to being in the ES group.
There was an improvement in “off” UPDRS motor scores in GM1-treated subjects in Phase 
I of the study and symptom worsening in placebo-treated subjects that mirrored the change 
observed in the Comparison group. We previously suggested that the symptomatic effect 
from GM1 in PD may relate to functional improvement in residual dopaminergic neurons, a 
conclusion supported by data showing enhanced dopamine synthesis in residual dopamine 
neurons in a mouse model of Parkinsonism following GM1 treatment 17. In Phase II, ES 
subjects maintained some of the initial benefit of GM1 treatment and DS subjects showed 
benefit after switching to GM1 use and both treatment groups fared better than the 
Comparison subjects. We previously reported that such findings are suggestive of a potential 
disease-modifying effect of GM1. If GM1 levels are decreased in the PD brain 35, 36 then 
our GM1 replacement therapy may have provided a sufficient amount of GM1 to substantia 
nigra neurons to stabilize them and promote their survival. Although the precise mechanisms 
underlying the potential disease modifying effects of GM1 in PD are likely multi-factorial, 
as suggested by us previously 1, recent work by Hadaczek et al. 36 suggest a new potential 
neuroprotective role of GM1 based on its role in regulating GDNF signaling, a function 
necessary for maintaining the health of dopaminergic neurons. GM1 was shown to be 
required for assembly of the GDNF receptor and effective GDNF signaling was dependent 
on an adequate level of GM1 36. This is relevant as studies with GDNF infusion in PD 
patients have shown some clinical benefit as well as increases in putamenal 18F-dopa uptake 
on PET and postmortem evidence of increased tyrosine hydroxylase immunopositive nerve 
fibers, suggestive of terminal sprouting, in the infused putamen 37. The present imaging 
results showing less loss of BPND in GM1 treated subjects in several striatal regions versus 
Comparison subjects suggest improvement in imaging parameters as well as clinical status, 
providing further support for a potential disease modifying effect of GM1 in PD.
Preclinical studies with GM1 ganglioside in a variety of PD models, including MPTP-
treated monkeys 14, have reported neuroprotective or neurorestorative effects of GM1 and 
increased striatal dopamine and metabolite levels in GM1-treated animals as well as a 
possible terminal sprouting effect in the striatum14, 22, 38, 39. GM1 administered to MPTP-
exposed monkeys resulted in a significant increase in 3H-mazindol binding to dopamine 
transported sites in the striatum 19. Other studies also have reported increases in the 
dopamine innervation of the striatum in GM1-treated animals with nigrostriatal 
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lesions 16, 22. This, however, is the first clinical imaging study to suggest that GM1 
administration to PD patients might slow the loss of dopamine terminals, detected by 
measuring binding of [11C]MP to dopamine transporter sites, and perhaps at least in some 
subjects in some striatal regions, even increase the number of dopamine terminals. These 
data are consistent with the findings from GDNF infusion studies mentioned above.
Previous studies (CALM-PD-CIT 40, REAL-PET41) have suggested a slowing in disease 
progression based on either SPECT imaging of the dopamine transporter (CALM-PD) 
or 18F-dopa positron emission tomography (REAL-PET) in PD patients taking pramipexole 
or ropinirole, respectively, compared to patients taking levodopa. Although results from 
these imaging studies suggested that both pramipexole and ropinirole were potentially 
neuroprotective (i.e., both studies reported a slower loss of BPND over time in subjects with 
agonist treatment compared to subjects receiving L-dopa), the imaging findings were not 
supported by clinical observations of the subjects. Several potential reasons for the 
discrepancy between clinical and imaging findings in these studies have been suggested 
including confounding of UPDRS scores by anti-PD medications despite patient evaluations 
in a “defined off” state 40 and drug-related differences in dopamine transporter binding 
regulation 42, as the dopamine transporter is a highly regulated protein 43. The effects of 
levodopa and ambient dopamine levels on dopamine transporter binding are unclear 44. 
Striatal dopamine transporter levels may be up-regulated in a state of synaptic dopamine 
excess and down-regulated in a dopamine-deficient condition, with the latter serving to 
maximize the efficacy of the remaining dopamine. However, under some conditions the 
dopamine transporter might actually be down-regulated by a treatment that enhances 
dopaminergic function in the human 44. It is unlikely that the effects observed in the current 
study can be substantially attributed to effects of levodopa on dopamine transporter 
regulation. However, it is possible that improved dopamine neurotransmission in GM1-
treated subjects may have had an effect on dopamine transporter binding.
This study has several potential limitations. This pilot imaging sub-study as well as the 
overall clinical trial was conducted only at a single site. Only a small number of subjects 
enrolled in the larger clinical study consented to participate in the imaging study and thus 
there may have been some selection bias and systematic differences between the groups. 
However, subjects in the two treatment groups were very well matched and only mean time 
since diagnosis, a rather imprecise measure, was significantly different between the three 
study groups at baseline. The time from diagnosis to participation in this study was longer 
for subjects in the Comparison group compared to the subjects in the treatment groups. 
While this may suggest that these subjects were studied at a slightly different point in the 
course of their disease, time from diagnosis is an imprecise measure of disease duration. 
Arguing against a significant clinical difference between the groups is the finding that 
Comparion group subjects and DS subjects (receiving placebo) showed the same rate of 
symptom progression during the first 6 months of the study. Due to the small number of 
subjects studied and the pilot nature of the study, our analysis is mainly descriptive and 
exploratory. P-values are provided for group comparisons but were not adjusted for multiple 
testing and as such, statistical significance should be interpreted with caution. This study 
also utilized subjects already receiving anti-PD medications, including dopamine agonists 
and levodopa, and use of these medications could have influence the imaging results. 
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Although clinical results were obtained and imaging studies were performed during a 
practically defined “off” period, it is possible that long-lasting effects of these medications 
on dopamine neurotransmission and the dopamine transporter site may have contributed to 
some of the present findings. However, there was no significant difference between the 
groups in regard to levodopa or dopamine agonist use. An additional limitation is the choice 
of the PET radioligand [11C ]MP and its targeting of DAT. While MP is not the most 
selective and highest affinity ligand for DAT (in comparison with tropanes, for example 
[11C] Win 35,428 45, [123I]CIT, [11C]Altropane), it was chosen in part because its reversible 
kinetics did not require a radial arterial input function with radioactive plasma 
measurements and metabolites assessment. Also the measurement of DAT by any PET or 
SPECT radioligand could be modulated by endogenous dopamine or medications. 
Nevertheless MP is a well established radioligand for DAT measures and DAT is a well 
established measure for evaluating the presynaptic dopamine system in PD.
5. Conclusion
The clinical results of a previously reported delayed start trial of GM1 in PD 1, and results of 
a previous 5 year open extension trial of GM1 in PD 24 suggest that long term use of GM1 
may result in a slower than expected progression of symptoms. The current PET imaging 
findings, although preliminary, provide additional data to suggest a potential disease 
modifying effect of GM1 on PD. These preliminary results need to be confirmed in a larger 
number of subjects and within the context of a larger, multi-center study.
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• PET imaging data were obtained from subjects enrolled in a trial of GM1 in PD.
• Striatal [11C]methylphenidate binding potential values (BPND) were analyzed.
• GM1 use was associated with slowed symptom progression.
• Imaging results showed significant slowing of BPND loss in several striatal 
regions.
• Results provide additional data supporting a disease modifying effect of GM1 
on PD.
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Changes in Unified Parkinson’s Disease Rating Scale (UPDRS) Motor Subsection Scores 
for the subset of subjects participating in the imaging study. The mean (±SEM) change from 
baseline (observed scores) in Early-start (N = 15) and Delayed-start (N = 14) sub-study 
subjects and in the standard-of-care Comparison group (N = 11), assessed in the practically 
defined “off” condition. The dashed vertical line at week 24 indicates the end of study Phase 
I. The dashed vertical line at week 120 indicates the end of study Phase II. The horizontal 
dashed line indicates baseline level. An increase of score indicates symptom worsening; a 
decrease in score indicates symptom improvement.
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Averaged striatal binding potential images at baseline (Week 0 for the Comparison group 
(C) subjects (N = 11)) [left panel] and at the transition point in the delayed start study (Week 
24 for Delayed-start (DS: N = 14) [middle panel] and Early-start (ES: N = 15) [right panel] 
groups) (top row) and averaged images obtained 2 years later at the end of the second phase 
of study during which all treatment subjects used GM1 ganglioside. Images show less loss 
of BPND over time in ES subjects and DS subjects versus Comparison group subjects. The 
far right panel demonstrates the averaged images of the MRIs of all participants.
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Table 1








Age (years) 60.0 (8.9) 59.9 (9.4) 59.0 (12.8) 0.9652
Sex: n (%)
    Male 11 (73.3) 9 (64.3) 10 (90.9) 0.3158
    Female 4 (26.7) 5 (35.7) 1 (9.1)
Mean time since diagnosis (years) 1.8 (1.1) 2.4 (2.0) 5.0 (3.9) 0.0055
Median, Range (years) 1.5, 0.5 – 3.9 1.5, 0.4 – 6.1 3.8, 1.5 – 13.2
MMSE score 29.0 (1.0) 28.6 (1.3) 29.5 (0.9) 0.1483
BDI-II score 4.7 (2.8) 5.4 (3.3) 3.8 (2.9) 0.4758
Total UPDRS score (Off) 29.3 (8.3) 28.7 (10.3) 36.7 (10.8) 0.1493
UPDRS Motor score (Off) 19.3 (6.9) 20.6 (6.4) 24.3 (6.7) 0.0760
UPDRS ADL score (Off) 8.4 (3.2) 9.1 (4.1) 10.6 (4.5) 0.3770
UPDRS Mentation score (Off) 0.6 (1.3) 0.6 (0.8) 0.8 (1.1) 0.8136
Medication Usage
Levodopa (# of subjects (percent)) 10 (66.7) 10 (71.4) 8 (72.7) 0.1681
Dopamine Agonist* (# of subjects (percent)) 10 (66.7) 9 (64.3) 9 (81.8) 0.8093
Selegiline (# of subjects (percent)) 5 (33.3) 5 (35.7) 4 (36.4) 0.4686
Levodopa Equivalent Dose (mg/d) 300.8 (183.4) 420.3 (274.3) 544.1 (239.0) 0.0611
Data presented as mean ± SD, unless otherwise noted. Levodopa equivalent dose calculations exclude 1 Comparison group subject who was 
unmedicated at baseline.
*
Dopamine agonists included pramipexole, ropinirole, pergolide and bromocriptine.
1
P value was from one-way ANOVA for continuous variables and Kruskal-Wallis test for categorical variables for testing the differences between 
Early-Start, Delayed-Start and Comparison groups.
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Table 2
Estimated Mean BPND Loss (95% CI) From Baseline to End of Study Phase I (6 Months).
Region Early Start (N=15) Delayed Start (N=14) p
LtaCN −0.04 (−0.14, 0.07) 0.07 (−0.02, 0.16) 0.11
LtaPu −0.01 (−0.08, 0.07) 0.06 (−0.01, 0.12) 0.19
LtpCN 0.02 (−0.09, 0.14) 0.08 (−0.02, 0.18) 0.44
LtpPu 0.00 (−0.04, 0.04) 0.02 (−0.02, 0.06) 0.53
LtvS −0.04 (−0.15, 0.08) 0.04 (−0.06, 0.14) 0.35
RtaCN −0.01 (−0.09, 0.07) 0.09 (0.02, 0.16) 0.09
RtaPu −0.01 (−0.05, 0.03) 0.04 (−0.00, 0.07) 0.08
RtpCN 0.01 (−0.08, 0.11) 0.07 (−0.01, 0.15) 0.38
RtpPu −0.01 (−0.06, 0.05) 0.07 (0.02, 0.11) 0.04
RtvS 0.07 (−0.02, 0.15) 0.01 (−0.07, 0.09) 0.35
LtaCN – left anterior caudate nucleus; LtaPu = left anterior putamen; LtpCN = left posterior caudate nucleus; LtpPu = left posterior putamen; LtvS 
= left ventral striatum; RtaCN = right anterior caudate nucleus; RtaPu = right anterior putamen; RtpCN = right posterior caudate nucleus; RtpPu = 
right posterior putamen; RtvS = right ventral striatum. A negative number indicates gain in BPND.
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Table 3
Estimated Mean BPND Loss (95% CI) From Baseline to End of First 12 Months of Study Phase II for Early-
Start and Delayed Start Groups.
Region Early-Start (ES)
(GM1 used for 18
mos)
Delayed-Start (DS)
(GM1 used for 12
mos)
Comparison (C)





LtaCN −0.01 (−0.11, 0.09) 0.10 (0.01, 0.19) 0.15 (0.04, 0.25) 0.030 0.194
LtaPu 0.06 (−0.01, 0.13) 0.10 (0.03, 0.17) 0.09 (0.01, 0.16) 0.564 0.645
LtpCN 0.01 (−0.11, 0.12) 0.06 (−0.05, 0.16) 0.08 (−0.04, 0.20) 0.391 0.581
LtpPu 0.02 (−0.02, 0.06) 0.04 (−0.00, 0.08) 0.05 (0.00, 0.09) 0.396 0.415
LtvS −0.02 (−0.13, 0.09) 0.03 (−0.07, 0.13) 0.05 (−0.07, 0.16) 0.428 0.695
RtaCN 0.01 (−0.07, 0.08) 0.13 (0.05, 0.20) 0.10 (0.02, 0.19) 0.086 0.670
RtaPu −0.01 (−0.05, 0.03) 0.05 (0.02, 0.09) 0.05 (0.01, 0.09) 0.049 0.560
RtpCN 0.01 (−0.08, 0.10) 0.09 (0.01, 0.18) 0.18 (0.08, 0.27) 0.016 0.046
RtpPu 0.01 (−0.05, 0.06) 0.06 (0.02, 0.11) 0.12 (0.07, 0.18) 0.002 0.013
RtvS 0.04 (−0.04, 0.13) 0.09 (0.01, 0.17) 0.06 (−0.03, 0.15) 0.799 0.982
LtaCN – left anterior caudate nucleus; LtaPu = left anterior putamen; LtpCN = left posterior caudate nucleus; LtpPu = left posterior putamen; LtvS 
= left ventral striatum; RtaCN = right anterior caudate nucleus; RtaPu = right anterior putamen; RtpCN = right posterior caudate nucleus; RtpPu = 
right posterior putamen; RtvS = right ventral striatum. A negative number indicates gain in BPND. Bx = Baseline (start of study). Early-Start (N 
=15); Delayed-Start (N =14); Comparison (N =11). P-values were calculated for comparing change over 18 months in the DS and ES arms vs the 
extrapolated change over 18 months in the comparison group (1.5 x change from Bx to 12 months).
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Table 4
Estimated Mean BPND Loss (95% CI) From Baseline to End of Study Phase II for Early-Start and Delayed 
Start Groups.
Region Early-Start (ES)
(GM1 used for 30
mos)
Delayed-Start (DS)
(GM1 used for 24
mos)
Comparison (C)





LtaCN 0.06 (−0.04, 0.16) 0.16 (0.07, 0.26) 0.30 (0.16, 0.43) 0.002 0.035
LtaPu 0.09 (0.02, 0.16) 0.14 (0.07, 0.21) 0.18 (0.09, 0.28) 0.055 0.199
LtpCN 0.11 (−0.01, 0.22) 0.11 (0.00, 0.22) 0.21 (0.06, 0.36) 0.150 0.162
LtpPu 0.04 (−0.00, 0.08) 0.06 (0.02, 0.11) 0.07 (0.01, 0.12) 0.318 0.654
LtvS 0.00 (−0.11, 0.11) 0.10 (−0.01, 0.21) 0.17 (0.02, 0.31) 0.058 0.312
RtaCN 0.10 (0.02, 0.18) 0.16 (0.08, 0.24) 0.21 (0.11, 0.31) 0.032 0.173
RtaPu 0.02 (−0.02, 0.06) 0.06 (0.02, 0.10) 0.07 (0.02, 0.12) 0.093 0.553
RtpCN 0.11 (0.02, 0.21) 0.13 (0.05, 0.22) 0.29 (0.17, 0.41) 0.007 0.012
RtpPu 0.07 (0.02, 0.12) 0.13 (0.08, 0.18) 0.17 (0.10, 0.24) 0.005 0.099
RtvS 0.13 (0.04, 0.22) 0.15 (0.07, 0.23) 0.15 (0.04, 0.26) 0.500 0.669
LtaCN – left anterior caudate nucleus; LtaPu = left anterior putamen; LtpCN = left posterior caudate nucleus; LtpPu = left posterior putamen; LtvS 
= left ventral striatum; RtaCN = right anterior caudate nucleus; RtaPu = right anterior putamen; RtpCN = right posterior caudate nucleus; RtpPu = 
right posterior putamen; RtvS = right ventral striatum. A negative number indicates gain in BPND. Bx = Baseline (start of study). Early-Start (N 
=15); Delayed-Start (N =14); Comparison (N =11). P-values were calculated for comparing change over 30 months in the DS and ES arms vs the 
extrapolated change over 30 months in the comparison group (1.25 x change from Bx to 24 months).
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Table 5
Estimated Mean BPND Loss (95% CI) From End of Study Phase I (6 Months) to the End of Study Phase II.
Region Delayed Start:









LtaCN 0.09 (0.00, 0.18) 0.30 (0.16, 0.43) 0.012
LtaPu 0.08 (0.02, 0.14) 0.18 (0.09, 0.28) 0.080
LtpCN 0.03 (−0.07, 0.13) 0.21 (0.06, 0.36) 0.049
LtpPu 0.04 (0.01, 0.08) 0.07 (0.01, 0.12) 0.520
LtvS 0.06 (−0.04, 0.16) 0.17 (0.02, 0.31) 0.250
RtaCN 0.07 (0.00, 0.14) 0.21 (0.11, 0.31) 0.033
RtaPu 0.03 (−0.01, 0.06) 0.07 (0.02, 0.12) 0.210
RtpCN 0.07 (−0.01, 0.15) 0.29 (0.17, 0.41) 0.003
RtpPu 0.06 (0.02, 0.11) 0.17 (0.10, 0.24) 0.012
RtvS 0.14 (0.06, 0.22) 0.15 (0.04, 0.26) 0.900
LtaCN – left anterior caudate nucleus; LtaPu = left anterior putamen; LtpCN = left posterior caudate nucleus; LtpPu = left posterior putamen; LtvS 
= left ventral striatum; RtaCN = right anterior caudate nucleus; RtaPu = right anterior putamen; RtpCN = right posterior caudate nucleus; RtpPu = 
right posterior putamen; RtvS = right ventral striatum. A negative number indicates gain in BPND. Delayed-Start (N =14); Comparison (N =11)
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